![](https://endpts.com/wp-content/uploads/2021/04/Chris-Martin-ADC-Therapeutics-tile-scaled.jpg)
Chris Martin, ADC Therapeutics CEO
ADC Therapeutics sells off royalty share for lead antibody-drug conjugate in $325M deal
ADC Therapeutics will receive $225 million in cash and an additional $100 million in near-term milestones as part of a royalty …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.